IRIDEX Corporation (IRIX)
IRIX Stock Price Chart
Explore IRIDEX Corporation interactive price chart. Choose custom timeframes to analyze IRIX price movements and trends.
IRIX Company Profile
Discover essential business fundamentals and corporate details for IRIDEX Corporation (IRIX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
16 Feb 1996
Employees
93.00
Website
https://www.iridex.comCEO
Patrick Mercer
Description
IRIDEX Corporation is a medical technology firm specializing in ophthalmology. They develop and supply advanced therapeutic laser systems, various delivery instruments, and essential consumable tools designed to address vision-threatening ocular conditions. Their product portfolio includes several laser consoles, each tailored for specific eye conditions. The Cyclo G6 system is specifically engineered for glaucoma treatment. For ailments like diabetic macular edema and other retinal pathologies, IRIDEX provides the IQ 532 and IQ 577 laser photocoagulation systems. Furthermore, the OcuLight series, encompassing models such as TX, SL, SLx, GL, and GLx, offers solutions for managing severe retinal issues like proliferative diabetic retinopathy, macular holes, and retinal tears or detachments. Beyond laser consoles, the company also manufactures specialized delivery instruments. These include the TxCell scanning laser delivery system, which empowers clinicians with multi-spot pattern scanning capabilities. A unique slit lamp adapter enables practitioners to integrate standard slit lamps into their diagnostic and therapeutic workflows. Additionally, a laser indirect ophthalmoscope is available for interventions targeting peripheral retinal disorders. IRIDEX's offerings extend to various probes. The MicroPulse P3 Probe, when coupled with the Cyclo G6 laser system, facilitates MicroPulse transscleral laser therapy. For managing uncontrolled glaucoma, the G-Probe is employed, while both the G-Probe and G-Probe Illuminate are utilized in procedures addressing refractory glaucoma. The EndoProbe product line supports a range of vitrectomy procedures. Their diverse client base spans ophthalmology professionals, academic and research hospitals, government healthcare facilities, specialized surgical centers, general hospitals, veterinary clinics, and private medical practices. Product distribution is handled via an internal and independent sales network across the United States, supplemented by independent distributors for its international markets. Originally incorporated in 1989 as IRIS Medical Instruments, Inc., the company adopted the name IRIDEX Corporation in November 1995. Its corporate headquarters are situated in Mountain View, California.
IRIX Financial Timeline
Browse a chronological timeline of IRIDEX Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Aug 2026
EPS estimate is -$0.01, while revenue estimate is $13.59m.
Earnings released on 19 May 2026
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $11.80m , missing expectations by -0.93%.
Earnings released on 26 Mar 2026
EPS came in at -$0.01 surpassing the estimated -$0.02 by +50.00%, while revenue for the quarter reached $14.72m , missing expectations by -0.11%.
Earnings released on 11 Nov 2025
EPS came in at -$0.09 falling short of the estimated -$0.02 by -350.00%, while revenue for the quarter reached $12.48m , missing expectations by -15.31%.
Earnings released on 12 Aug 2025
EPS came in at -$0.06 surpassing the estimated -$0.09 by +33.33%, while revenue for the quarter reached $13.57m , beating expectations by +3.60%.
Earnings released on 13 May 2025
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $11.90m , missing expectations by -1.69%.
Earnings released on 27 Mar 2025
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $12.70m , missing expectations by -0.81%.
Earnings released on 12 Nov 2024
EPS came in at -$0.12 falling short of the estimated -$0.09 by -33.33%, while revenue for the quarter reached $11.58m , missing expectations by -7.35%.
Earnings released on 8 Aug 2024
EPS came in at -$0.16 falling short of the estimated -$0.12 by -33.33%, while revenue for the quarter reached $12.63m , beating expectations by +0.25%.
Earnings released on 14 May 2024
EPS came in at -$0.21 falling short of the estimated -$0.12 by -75.00%, while revenue for the quarter reached $11.76m , missing expectations by -1.99%.
Earnings released on 26 Mar 2024
EPS came in at -$0.18 falling short of the estimated -$0.05 by -260.00%, while revenue for the quarter reached $12.46m , missing expectations by -16.39%.
Earnings released on 14 Nov 2023
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $12.85m , missing expectations by -10.45%.
Earnings released on 10 Aug 2023
EPS came in at -$0.17 falling short of the estimated -$0.11 by -54.55%, while revenue for the quarter reached $12.86m , missing expectations by -9.66%.
Earnings released on 11 May 2023
EPS came in at -$0.13 falling short of the estimated -$0.12 by -8.33%, while revenue for the quarter reached $13.71m , missing expectations by -4.55%.
Earnings released on 9 Mar 2023
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%, while revenue for the quarter reached $15.20m , beating expectations by +0.23%.
Earnings released on 10 Nov 2022
EPS came in at -$0.11 surpassing the estimated -$0.15 by +26.67%, while revenue for the quarter reached $14.64m , beating expectations by +5.54%.
Earnings released on 15 Aug 2022
EPS came in at -$0.14 surpassing the estimated -$0.16 by +12.50%, while revenue for the quarter reached $13.76m , missing expectations by -1.22%.
Earnings released on 12 May 2022
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%, while revenue for the quarter reached $13.39m , missing expectations by -0.21%.
Earnings released on 10 Mar 2022
EPS came in at -$0.15 falling short of the estimated -$0.11 by -36.36%, while revenue for the quarter reached $15.25m , beating expectations by +3.85%.
Earnings released on 11 Nov 2021
EPS came in at -$0.14 surpassing the estimated -$0.15 by +6.67%, while revenue for the quarter reached $13.26m , missing expectations by -6.25%.
Earnings released on 12 Aug 2021
EPS came in at -$0.09 surpassing the estimated -$0.16 by +43.75%, while revenue for the quarter reached $13.43m , meeting expectations.
IRIX Stock Performance
Access detailed IRIX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
